Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 148 participants.

Also called NCT02488252

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 148 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02488252
Other papers using this trial's data
  • Add-on Rehmannia-6-Based Chinese Medicine in Type 2 Diabetes and CKD: A Multicenter Randomized Controlled Trial Clinical journal of the American Society of Nephrology : CJASN, 2023-09-01 DOI, PubMed 37307005, PMC10564374 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02488252. Randomized; single masking; primary purpose treatment. Start 2015-07 (actual); primary completion 2021-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy
Acronym
SCHEMATIC
Condition
Diabetic Nephropathies
Intervention (Drug)
Semi-individualised Chinese Medicine treatment
Intervention (Drug)
Routine medical care (active comparator)
Lead sponsor
The University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct02488252
Content hash
3bfe5d62fc89eda82b7b47fc00c492c064144627f00677c42d3de456949a9c12